A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity

N,N-dimethyltryptamine (DMT) is a methylated indolealkylamine found widely in plants and detected in animal tissues, where it is considered an endogenous trace amine. Earlier research has focused predominantly on DMT's potent psychotropic and hallucinogenic effects, leaving its potential physiological roles poorly understood. The enzyme indolethylamine-N-methyltransferase (INMT), which synthesises DMT from tryptamine, is expressed most strongly in peripheral tissues (lungs, thyroid, adrenal gland) and only sparsely in the brain; nonetheless, evidence for active uptake mechanisms across the blood–brain barrier suggests peripheral synthesis could influence central nervous system function. Overall, the ubiquity of DMT across species and the specialised transport and storage processes that have been reported raise questions about functions beyond hallucination or toxicity. Frecska and colleagues set out to review and integrate literature bearing on non-psychedelic roles of DMT, emphasising its recently reported activity at the sigma-1 receptor (Sig-1R). The paper surveys evidence on DMT biosynthesis and biodistribution, Sig-1R biology and cellular bioenergetics, serotonergic mechanisms in immunoregulation, and data on INMT expression in cancer. The stated aim is to propose that DMT may participate in adaptive cellular protective mechanisms—such as protection from hypoxia, modulation of immunity, and effects on tissue regeneration—and to suggest directions for further experimental research and potential medical applications.

This paper is a narrative literature overview rather than a primary empirical study. The authors synthesise findings from biochemical, cellular, animal, and human studies to build a multi-level argument about DMT's potential physiological roles. Key thematic areas reviewed include DMT biosynthesis and tissue distribution, mechanisms of neuronal uptake and storage, pharmacology at serotonin and sigma-1 receptors, experimental models of Sig-1R-mediated cytoprotection, immunity-related observations (including in vitro and small-scale human data), and gene-expression studies of INMT in cancer. The extracted text does not report a formal search strategy, inclusion/exclusion criteria, databases searched, or a risk-of-bias assessment; therefore it is not possible to reconstruct systematic review methods. Instead, the investigators draw on selected experimental reports and clinical observations to form converging hypotheses. Where the original studies used different modalities (for example, in vitro assays, animal ischaemia models, and human observational data), the authors integrate these heterogeneous sources to discuss mechanistic plausibility and translational implications. When specific experimental details are cited (for example, reports of rapid brain uptake and prolonged persistence of DMT after peripheral administration), those findings are described as background evidence supporting the proposed uptake and storage mechanisms.

Biosynthesis and biodistribution: The review summarises biochemical pathways by which tryptophan is decarboxylated to tryptamine and then methylated by INMT using S-adenosyl methionine to produce DMT. INMT is reported to be highly expressed in peripheral tissues—notably lung, thyroid and adrenal gland—with intermediate expression in placenta, muscle, heart, gut and lymph nodes; brain expression is said to be limited, aside from the pineal gland. To reconcile peripheral synthesis with central effects, the authors describe a three-step uptake hypothesis: (1) active transport across the blood–brain barrier, (2) neuronal uptake via the serotonin transporter, and (3) sequestration into synaptic vesicles via the vesicular monoamine transporter 2. Empirical reports are cited that peripheral DMT can enter the brain within seconds, persist for days in animal models, and be stored in vesicles for at least a week, implying potential for high intracellular and releasable concentrations. Receptor pharmacology: DMT interacts with multiple receptor systems. The classical hallucinogenic mechanism is commonly ascribed to serotonin (5-HT) receptors, particularly 5-HT2 subtypes; DMT has agonist affinity at 5-HT2C and other serotonergic sites, though tolerance patterns and some behavioural/intracellular findings suggest serotonergic action alone does not explain all effects. More recently, DMT has been reported to act as an endogenous ligand at the sigma-1 receptor (Sig-1R), an intracellular receptor located at the endoplasmic reticulum–mitochondrion interface that modulates calcium signalling and cellular bioenergetics. While some Sig-1R-mediated effects reported in vitro require micromolar ligand concentrations, the proposed neuronal uptake and vesicular storage mechanisms are offered to explain how such concentrations might be reached in vivo. Sigma-1 receptor effects and cytoprotection: The review summarises evidence from cellular and animal models that Sig-1R agonists regulate mitochondrial function, reduce oxidative stress, attenuate intracellular calcium overload, preserve anti-apoptotic genes (for example Bcl-2), and promote neurite outgrowth and spine morphology changes indicative of neuronal plasticity. Sig-1R modulation is reported to be protective in a variety of ischaemia, organopathy and neurotoxicity paradigms, although some assays show paradoxical findings depending on cell type and assay conditions. The authors note co-localisation of INMT and Sig-1R at C-boutons on spinal motor neurons and discuss data indicating Sig-1R activation can reduce motor neuron excitability—an effect the authors suggest could lower muscle energy consumption under hypoxic stress. Clinical and developmental contexts: The review advances a speculative model in which peripheral DMT (for example, synthesised rapidly by lungs under extreme stress) enters the circulation and is taken up by the brain during life-threatening events such as cardiac arrest; subjective near-death phenomenology is noted as phenomenologically similar to DMT experiences. In the perinatal context, higher INMT activity in fetal or neonatal lungs is reported in animal data, and selective Sig-1R agonists have shown protection against excitotoxic perinatal brain injury in experimental settings. Immunoregulation and cancer-related findings: Sigma receptors are reported to be expressed on immune cells and in many tumour tissues. Sig-1R agonists are said to reduce pro-inflammatory cytokines while enhancing anti-inflammatory interleukin-10 in some pathological conditions. The authors cite human data suggesting ayahuasca (a DMT-containing decoction) increased circulating natural killer (NK) cells at doses as low as 1.0 mg DMT/kg body weight, and they report pilot in vitro findings in which DMT increased secretion and gene expression of type I and II interferons in human NK cells and dendritic cells without raising conventional inflammatory cytokine mRNA or protein levels. Several groups have observed down-regulation of INMT gene expression in recurrent prostate and lung cancers; the reviewers interpret these data to suggest a possible role for locally produced DMT in supporting immune surveillance or modulating the tumour microenvironment, but acknowledge direct tumour-suppressor effects of DMT are unlikely based on current knowledge.

Frecska and colleagues interpret the assembled evidence as converging on a broader physiological role for DMT beyond its classical identification as a hallucinogen. They propose that DMT, acting at intracellular Sig-1Rs and at serotonergic receptors, could participate in cellular protective processes that mitigate oxidative stress, regulate calcium homeostasis, support neuronal plasticity, and modulate immune responses. Such mechanisms are advanced as potentially adaptive in contexts of general or local hypoxia (for example cardiac arrest, stroke, myocardial infarction), during perinatal stress, and in processes relevant to tumour surveillance. The authors acknowledge substantial uncertainties and limitations. Much of the evidence is indirect and heterogeneous—comprising in vitro pharmacology, animal models, small-scale human observations, and gene-expression correlations in cancer—and no comprehensive experimental programme has yet established causality. They note specific concerns raised in the literature, such as the micromolar concentrations needed for Sig-1R effects in vitro and the lack of detailed, systematic data on endogenous DMT kinetics in humans. Policy obstacles are also discussed: DMT's Schedule I classification has constrained research. The reviewers call for focused experimental work to test the three-step uptake hypothesis, quantify INMT and DMT dynamics in stress states, clarify Sig-1R-mediated cellular effects in relevant tissues, and determine immunological consequences in vivo. Finally, the authors suggest cautious translational possibilities—ranging from emergency medicine through neonatal care and oncology—but stress these remain speculative until validated by targeted experiments.

The paper concludes that DMT is best regarded not merely as a psychedelic compound but as a bioactive endogenous molecule with plausible adaptive roles in cell protection, regeneration and immune regulation. The sigma-1 receptor emerges in the authors' synthesis as a likely mediator of many of these effects at the endoplasmic reticulum–mitochondria interface. While the recommendations for clinical application are bold—spanning resuscitation, intensive care, neurology, neonatal medicine, oncology and palliative care—the authors emphasise that these ideas rest on indirect evidence and require systematic experimental verification. They also note that traditional uses of DMT-containing preparations such as ayahuasca are consistent with the hypothesis that DMT can participate in healing or recuperative processes.